Sophie Lotersztajn

List of Publications by Year
in descending order

49 papers	5,368 citations	136740 32 h-index	214527 47 g-index
49 all docs	49 docs citations	49 times ranked	7120 citing authors

#	Article	IF	Citations
1	Inflammation in alcohol-associated liver disease progression. Zeitschrift Fur Gastroenterologie, 2022, 60, 58-66.	0.2	2
2	Targeting cell-intrinsic metabolism for antifibrotic therapy. Journal of Hepatology, 2021, 74, 1442-1454.	1.8	24
3	A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. Journal of Hepatology, 2020, 72, 528-538.	1.8	113
4	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Hepatology, 2020, 71, 1750-1765.	3.6	18
5	LC3-associated phagocytosis in myeloid cells, a fireman that restrains inflammation and liver fibrosis, via immunoreceptor inhibitory signaling. Autophagy, 2020, 16, 1526-1528.	4.3	13
6	Glutamate Signaling in Alcoholâ€associated Fatty Liver: â€œPas de Deuxâ€• Hepatology, 2020, 72, 350-352.	3.6	6
7	LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling. Science Translational Medicine, 2020, 12, .	5.8	48
8	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	2.2	39
9	Mucosal-associated invariant T cells and disease. Nature Reviews Immunology, 2019, 19, 643-657.	10.6	197
10	Autophagy in liver diseases: Time for translation?. Journal of Hepatology, 2019, 70, 985-998.	1.8	252
11	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. Journal of Lipid Research, 2019, 60, 1284-1292.	2.0	27
12	In vitro distinction between proinflammatory and antiinflammatory macrophages with gadoliniumâ€liposomes and ultrasmall superparamagnetic iron oxide particles at 3.0T. Journal of Magnetic Resonance Imaging, 2019, 49, 1166-1173.	1.9	4
13	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut, 2019, 68, 522-532.	6.1	59
14	Interleukinsâ€17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation. Hepatology Communications, 2018, 2, 329-343.	2.0	19
15	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications, 2018, 9, 2146.	5.8	152
16	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	1.8	26
17	Autophagy in chronic liver diseases: the two faces of Janus. American Journal of Physiology - Cell Physiology, 2017, 312, C263-C273.	2.1	62
18	Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model. Environmental Health Perspectives, 2017, 125, 428-436.	2.8	98

#	Article	IF	Citations
19	Statins Modulate Cyclooxygenaseâ€2 and Microsomal Prostaglandin E Synthaseâ€1 in Human Hepatic Myofibroblasts. Journal of Cellular Biochemistry, 2016, 117, 1176-1186.	1.2	9
20	Targeting cannabinoid receptors in hepatocellular carcinoma?. Gut, 2016, 65, 1582-1583.	6.1	5
21	The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. Scientific Reports, 2016, 6, 28806.	1.6	75
22	Macrophage autophagy protects against liver fibrosis in mice. Autophagy, 2015, 11, 1280-1292.	4.3	210
23	Autophagy: A Multifaceted Partner in Liver Fibrosis. BioMed Research International, 2014, 2014, 1-7.	0.9	77
24	M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology, 2014, 59, 130-142.	3.6	450
25	Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology, 2014, 59, 296-306.	3.6	93
26	When Autophagy Chaperones Liver Metabolism. Cell Metabolism, 2014, 20, 392-393.	7.2	1
27	M2 Kupffer Cells Promote Hepatocyte Senescence. American Journal of Pathology, 2014, 184, 1763-1772.	1.9	51
28	Reply. Hepatology, 2014, 59, 353-354.	3.6	0
29	Cannabinoid signaling and liver therapeutics. Journal of Hepatology, 2013, 59, 891-896.	1.8	119
30	Cellular Mechanisms of Tissue Fibrosis. 5. Novel insights into liver fibrosis. American Journal of Physiology - Cell Physiology, 2013, 305, C789-C799.	2.1	191
31	Pathophysiology of NASH: Perspectives for a Targeted Treatment. Current Pharmaceutical Design, 2013, 19, 5250-5269.	0.9	140
32	The liver X receptor in hepatic stellate cells: A novel antifibrogenic target?. Journal of Hepatology, 2011, 55, 1452-1454.	1.8	10
33	Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology, 2011, 54, 1217-1226.	3.6	214
34	Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB ₁) receptors in the regenerating liver. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6323-6328.	3.3	90
35	Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology, 2010, 52, 1046-1059.	3.6	93
36	Endocannabinoids in the pathophysiology of obesity â€“ The liver. Drug Discovery Today Disease Mechanisms, 2010, 7, e185-e190.	0.8	0

#	Article	IF	Citations
37	Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis. PLoS ONE, 2009, 4, e5844.	1.1	189
38	The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusionâ€induced cardiomyopathy. FASEB Journal, 2009, 23, 2120-2130.	0.2	116
39	Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity. Diabetes, 2009, 58, 125-133.	0.3	127
40	Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C. Gastroenterology, 2008, 134, 432-439.	0.6	174
41	Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opinion on Therapeutic Targets, 2007, 11, 403-409.	1.5	56
42	The sphingosine 1â€phosphate receptor S1P 2 triggers hepatic wound healing. FASEB Journal, 2007, 21, 2005-2013.	0.2	77
43	CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine, 2006, 12, 671-676.	15.2	476
44	Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology, 2005, 42, 63-71.	3.6	269
45	Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology, 2005, 128, 742-755.	0.6	420
46	HEPATIC FIBROSIS: Molecular Mechanisms and Drug Targets. Annual Review of Pharmacology and Toxicology, 2005, 45, 605-628.	4.2	288
47	Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts. Journal of Hepatology, 2004, 41, 407-413.	1.8	23
48	Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology, 2003, 125, 460-469.	0.6	72
49	Platelet-derived Growth Factor-BB and Thrombin Generate Positive and Negative Signals for Human Hepatic Stellate Cell Proliferation. Journal of Biological Chemistry, 1998, 273, 27300-27305.	1.6	94